Articles / The Real Story on a COVID-19 vaccine
0 hours
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
0 hours
These are activities that require reflection on feedback about your work.
0 hours
These are activities that use your work data to ensure quality results.
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
These are activities that require reflection on feedback about your work.
These are activities that use your work data to ensure quality results.
This week’s expert: Prof Ian Frazer, Clinical Immunologist; Researcher for Vaccine Development, Faculty of Medicine, The University of QLD.
Drawn from an interview with Clinical Immunologist Prof Ian Frazer by Dr Harry Nespolon on the Healthed podcast Going Viral.
• Based on our knowledge about immunisation against other coronaviruses both in animals and humans, if we do get a vaccine against SARS-CoV-2, it is unlikely to be highly immunogenic or confer long-term immunity.
• The major challenge exists because SARS-CoV-2 affects the respiratory tract, where the immune system is distinct from the rest of the body. Currently the problem is that we are trying to get a vaccine that is delivered systemically to specifically and significantly affect the immune system in the respiratory tract.
RSV and the Heart
Oral Contraceptive Pill in Teens
Menopausal Hormone Therapy - What Dose of Estrogen is Best?
Cardiovascular Benefits of GLP1s – New Evidence
Modified but kept in place
Eliminated entirely without replacement
Maintained as is
Completely replaced with an alternative system
Listen to expert interviews.
Click to open in a new tab
Browse the latest articles from Healthed.
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.
Menopause and MHT
Multiple sclerosis vs antibody disease
Using SGLT2 to reduce cardiovascular death in T2D
Peripheral arterial disease